Citations (90)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Loreto Martinez-Gonzalez & Ana Martinez. (2023) Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs 32:2, pages 141-160.
Read now
Read now
Francisco Espejo-Porras, Javier Fernández-Ruiz & Eva de Lago. (2018) Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:5-6, pages 377-386.
Read now
Read now
Selim R Benbadis, Juan Sanchez-Ramos, Ali Bozorg, Melissa Giarratano, Kavita Kalidas, Lara Katzin, Derrick Robertson, Tuan Vu, Amanda Smith & Theresa Zesiewicz. (2014) Medical marijuana in neurology. Expert Review of Neurotherapeutics 14:12, pages 1453-1465.
Read now
Read now
. (2012) ALSUntangled No. 16: Cannabis. Amyotrophic Lateral Sclerosis 13:4, pages 400-404.
Read now
Read now
Javier Fernández-Ruiz, Concepción García, Onintza Sagredo, María Gómez-Ruiz & Eva de Lago. (2010) The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opinion on Therapeutic Targets 14:4, pages 387-404.
Read now
Read now
Silvia Rossi, Valentina De Chiara, Alessandra Musella, Mauro Cozzolino, Giorgio Bernardi, Mauro Maccarrone, Nicola B. Mercuri, Maria Teresa Carrì & Diego Centonze. (2010) Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 11:1-2, pages 83-90.
Read now
Read now
. (2009) THEME 1 THERAPEUTIC STRATEGIES. Amyotrophic Lateral Sclerosis 10:sup1, pages 67-83.
Read now
Read now
Natalya M. Kogan & Raphael Mechoulam. (2007) Cannabinoids in health and disease. Dialogues in Clinical Neuroscience 9:4, pages 413-430.
Read now
Read now
Ben A Bahr, David A Karanian, Sagar S Makanji & Alexandros Makriyannis. (2006) Targeting the endocannabinoid system in treating brain disorders. Expert Opinion on Investigational Drugs 15:4, pages 351-365.
Read now
Read now
. (2005) THEME 3 In vivo Experimental Models. Amyotrophic Lateral Sclerosis 6:sup1, pages 91-103.
Read now
Read now
Patrick Weydt, Soyon Hong, Anke Witting, Thomas Möller, Nephi Stella & Michel Kliot. (2005) Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis 6:3, pages 182-184.
Read now
Read now
Articles from other publishers (79)
Akila Muthuramalingam, Ashok Kumar Pandurangan & Subhamoy Banerjee. 2023. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases
170
186
.
Mohammad Uzair, Hammad Qaiser, Muhammad Arshad, Aneesa Zafar & Shahid Bashir. 2023. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases
147
169
.
Ahmed Hasbi, Bertha K. Madras & Susan R. George. (2023) Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. Brain Sciences 13:2, pages 325.
Crossref
Crossref
Ana Bernal‐Chico, Vanja Tepavcevic, Andrea Manterola, Carmen Utrilla, Carlos Matute & Susana Mato. (2022) Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells. Glia 71:1, pages 103-126.
Crossref
Crossref
Ira Agrawal, Yong Shan Lim, Shi-Yan Ng & Shuo-Chien Ling. (2022) Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine. Translational Neurodegeneration 11:1.
Crossref
Crossref
Yuma T. Ortiz, Lance R. McMahon & Jenny L. Wilkerson. (2022) Medicinal Cannabis and Central Nervous System Disorders. Frontiers in Pharmacology 13.
Crossref
Crossref
Carmen Rodríguez‐Cueto, Marta Gómez‐Almería, Laura García Toscano, Julián Romero, Cecilia J. Hillard, Eva de Lago & Javier Fernández‐Ruiz. (2021)
Inactivation of the CB
2
receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis
. Brain Pathology 31:6.
Crossref
Crossref
Claudio Giuliano, Miriam Francavilla, Gerardo Ongari, Alessandro Petese, Cristina Ghezzi, Nora Rossini, Fabio Blandini & Silvia Cerri. (2021) Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease. International Journal of Molecular Sciences 22:16, pages 8920.
Crossref
Crossref
Jenny L. Wilkerson, Joshua A. Bilbrey, Jasmine S. Felix, Alexandros Makriyannis & Lance R. McMahon. (2021) Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?. Pharmacology Biochemistry and Behavior 206, pages 173192.
Crossref
Crossref
Bijo Mathew, Seetha Harilal, Arafa Musa, Rajesh Kumar, Della Grace Thomas Parambi, Jobin Jose, Md. Sahab Uddin, Muhammad Ajmal Shah, Tapan Behl & Mazhuvancherry Kesavan Unnikrishnan. (2021) An Agathokakological Tale of Δ9-THC: Exploration of Possible Biological Targets. Current Drug Targets 22:7, pages 823-834.
Crossref
Crossref
Onesimus Mahdi, Mohamad T.H. Baharuldin, Nurul Huda M. Nor, Samaila M. Chiroma, Saravanan Jagadeesan & Mohamad A.M. Moklas. (2021) The Neuroprotective Properties, Functions, and Roles of Cannabis sativa in Selected Diseases Related to the Nervous System. Central Nervous System Agents in Medicinal Chemistry 21:1, pages 20-38.
Crossref
Crossref
Carmen Rodríguez‐Cueto, Laura García‐Toscano, Irene Santos‐García, Marta Gómez‐Almería, Claudia Gonzalo‐Consuegra, Francisco Espejo‐Porras, Javier Fernández‐Ruiz & Eva Lago. (2021)
Targeting the CB
2
receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis
. British Journal of Pharmacology 178:6, pages 1373-1387.
Crossref
Crossref
Frederique Wieters, Carolin Weiss Lucas, Matthias Gruhn, Ansgar Büschges, Gereon R. Fink & Markus Aswendt. (2021) Introduction to spasticity and related mouse models. Experimental Neurology 335, pages 113491.
Crossref
Crossref
Raju Dash, Md. Chayan Ali, Israt Jahan, Yeasmin Akter Munni, Sarmistha Mitra, Md. Abdul Hannan, Binod Timalsina, Diyah Fatimah Oktaviani, Ho Jin Choi & Il Soo Moon. (2021) Emerging potential of cannabidiol in reversing proteinopathies. Ageing Research Reviews 65, pages 101209.
Crossref
Crossref
Shravanthi Mouli, Sindhu Ramesh, Manoj Govindarajulu, Mohammed Almaghrabi, Ayaka Fujihashi, Rishi M. Nadar, Julia M. Salamat, Jack Deruiter, Randall C. Clark, Timothy Moore, Satyanarayana R. Pondugula, Dinesh Chandra Agrawal & Muralikrishnan Dhanasekaran. 2021. Medicinal Herbs and Fungi. Medicinal Herbs and Fungi
203
226
.
Erin M. Rock & Linda A. Parker. 2021. Cannabinoids and Neuropsychiatric Disorders. Cannabinoids and Neuropsychiatric Disorders
1
13
.
R. Cooray, V. Gupta & C. Suphioglu. (2020) Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review. Molecular Neurobiology 57:11, pages 4878-4890.
Crossref
Crossref
Vamsi Reddy, Dayton Grogan, Meenakshi Ahluwalia, Évila Lopes Salles, Pankaj Ahluwalia, Hesam Khodadadi, Katelyn Alverson, Andy Nguyen, Srikrishnan P. Raju, Pankaj Gaur, Molly Braun, Fernando L. Vale, Vincenzo Costigliola, Krishnan Dhandapani, Babak Baban & Kumar Vaibhav. (2020) Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies. EPMA Journal 11:2, pages 217-250.
Crossref
Crossref
Francisco Espejo-Porras, Laura García-Toscano, Carmen Rodríguez-Cueto, Irene Santos-García, Eva de Lago & Javier Fernandez-Ruiz. (2019)
Targeting glial cannabinoid CB
2
receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
. British Journal of Pharmacology 176:10, pages 1585-1600.
Crossref
Crossref
Berzenn Urbi, Maame Amma Owusu, Ian Hughes, Matthew Katz, Simon Broadley & Arman Sabet. (2019)
Effects of cannabinoids in Amyotrophic Lateral Sclerosis (
ALS
) murine models: a systematic review and meta‐analysis
. Journal of Neurochemistry 149:2, pages 284-297.
Crossref
Crossref
Vijay Kumar, Preeti Gupta & Md. Imtaiyaz Hassan. (2019) Mechanism and implications of traditional Chinese medicine in amyotrophic lateral sclerosis therapy. Journal of Proteins and Proteomics.
Crossref
Crossref
Nilo Riva, Gabriele Mora, Gianni Sorarù, Christian Lunetta, Ottavia E Ferraro, Yuri Falzone, Letizia Leocani, Raffaella Fazio, Mauro Comola, Giancarlo Comi, Fabio Formaglio, Paolo Rossi, Marta Clerici, Yuri Matteo Falzone, Laura Pozzi, Daniele Martinelli, Federica Cerri, Ignazio Diego Lopez, Filippo Martinelli-Boneschi, Angelo Quattrini, Elisabetta Pieri, Kalliopi Marinou, Giorgia Querin, Valeria Sansone, Eleonora Maestri, Andrea Calvo & Adriano Chio. (2019) Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology 18:2, pages 155-164.
Crossref
Crossref
Maria S. Aymerich, Ester Aso, Miguel A. Abellanas, Rosa M. Tolon, Jose A. Ramos, Isidre Ferrer, Julian Romero & Javier Fernández-Ruiz. (2018) Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochemical Pharmacology 157, pages 67-84.
Crossref
Crossref
Carmen Rodríguez-Cueto, Irene Santos-García, Laura García-Toscano, Francisco Espejo-Porras, MLuz Bellido, Javier Fernández-Ruiz, Eduardo Muñoz & Eva de Lago. (2018) Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Biochemical Pharmacology 157, pages 217-226.
Crossref
Crossref
Eric P. Baron. (2018) Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache: The Journal of Head and Face Pain 58:7, pages 1139-1186.
Crossref
Crossref
Valerio Chiurchiù, Mario van der Stelt, Diego Centonze & Mauro Maccarrone. (2018) The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. Progress in Neurobiology 160, pages 82-100.
Crossref
Crossref
Hebert Luis Hernández‐Montiel, Juan Carlos Solís‐S, Pablo‐García Solís, Mónica López Hidalgo, Nancy Georgina Hernández Chan, Lorena Asucena García Noguez, Julián Valeriano Reyes López, Ana Gabriela Hernández Puga, Haydé Azeneth Vergara Castañeda, Lorena Méndez Villa & Nelly Angélica Morales Guerrero. 2017. Fruit and Vegetable Phytochemicals. Fruit and Vegetable Phytochemicals
85
114
.
Noemi Pasquarelli, Michael Engelskirchen, Johannes Hanselmann, Sascha Endres, Christoph Porazik, Hanna Bayer, Eva Buck, Meliha Karsak, Patrick Weydt, Boris Ferger & Anke Witting. (2017) Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. Neuropharmacology 124, pages 157-169.
Crossref
Crossref
Thangavelu Soundara Rajan, Domenico Scionti, Francesca Diomede, Gianpaolo Grassi, Federica Pollastro, Adriano Piattelli, Lucio Cocco, Placido Bramanti, Emanuela Mazzon & Oriana Trubiani. (2017) Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. Journal of Cellular Biochemistry 118:4, pages 819-828.
Crossref
Crossref
María Fernández-Trapero, Francisco Espejo-Porras, Carmen Rodríguez-Cueto, Joan R. Coates, Carmen Pérez-Díaz, Eva de Lago & Javier Fernández-Ruiz. (2017) Up-regulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Disease Models & Mechanisms.
Crossref
Crossref
Vijay Kumar, Asimul Islam, Md. Imtaiyaz Hassan & Faizan Ahmad. (2016) Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning. European Journal of Medicinal Chemistry 121, pages 903-917.
Crossref
Crossref
Sabrina Giacoppo & Emanuela Mazzon. (2016) Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?. Neural Regeneration Research 11:12, pages 1896.
Crossref
Crossref
Zara A. Ioannides, Shyuan T. Ngo, Robert D. Henderson, Pamela A. McCombe & Frederik J. Steyn. (2016) Altered Metabolic Homeostasis in Amyotrophic Lateral Sclerosis: Mechanisms of Energy Imbalance and Contribution to Disease Progression. Neurodegenerative Diseases 16:5-6, pages 382-397.
Crossref
Crossref
Mary-Jeanne Kallman. 2016. Drug Discovery and Evaluation: Pharmacological Assays. Drug Discovery and Evaluation: Pharmacological Assays
1
50
.
Mary Jeanne Kallman. 2016. Drug Discovery and Evaluation: Pharmacological Assays. Drug Discovery and Evaluation: Pharmacological Assays
1553
1592
.
Richard S. Bedlack, Nanette Joyce, Gregory T. Carter, Sabrina Paganoni & Chafic Karam. (2015) Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis. Neurologic Clinics 33:4, pages 909-936.
Crossref
Crossref
Javier Fernández-Ruiz, María A. Moro & José Martínez-Orgado. (2015) Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics 12:4, pages 793-806.
Crossref
Crossref
Francisco Espejo-Porras, Fabiana Piscitelli, Roberta Verde, José A. Ramos, Vincenzo Di Marzo, Eva de Lago & Javier Fernández-Ruiz. (2015) Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. Journal of Neuroimmune Pharmacology 10:2, pages 233-244.
Crossref
Crossref
Valerio Chiurchiù, Alessandro Leuti & Mauro Maccarrone. (2015) Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses. Journal of Neuroimmune Pharmacology 10:2, pages 268-280.
Crossref
Crossref
Eva de Lago, Miguel Moreno-Martet, Francisco Espejo-Porras & Javier Fernández-Ruiz. 2015. Cannabinoids in Neurologic and Mental Disease. Cannabinoids in Neurologic and Mental Disease
99
123
.
Mary Jeanne Kallman. 2014. Drug Discovery and Evaluation: Pharmacological Assays. Drug Discovery and Evaluation: Pharmacological Assays
1
47
.
Sabrina Giacoppo, Giuseppe Mandolino, Maria Galuppo, Placido Bramanti & Emanuela Mazzon. (2014) Cannabinoids: New Promising Agents in the Treatment of Neurological Diseases. Molecules 19:11, pages 18781-18816.
Crossref
Crossref
Miguel Moreno-Martet, Francisco Espejo-Porras, Javier Fernández-Ruiz & Eva de Lago. (2014)
Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1
G93A
Transgenic Mice and Evaluation of a Sativex
®
-like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis
. CNS Neuroscience & Therapeutics 20:9, pages 809-815.
Crossref
Crossref
Giuseppe Di Iorio, Matteo Lupi, Fabiola Sarchione, Ilaria Matarazzo, Rita Santacroce, Filippo Petruccelli, Giovanni Martinotti & Massimo Di Giannantonio. (2013) The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases. International Journal of High Risk Behaviors and Addiction 2:3, pages 100-106.
Crossref
Crossref
Rachna S. Pandya, Haining Zhu, Wei Li, Robert Bowser, Robert M. Friedlander & Xin Wang. (2013) Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cellular and Molecular Life Sciences 70:24, pages 4729-4745.
Crossref
Crossref
Akshay Anand, Keshav Thakur & Pawan Kumar Gupta. (2013) ALS and Oxidative Stress: The Neurovascular Scenario. Oxidative Medicine and Cellular Longevity 2013, pages 1-14.
Crossref
Crossref
Miguel Moreno-Martet, Leyre Mestre, Frida Loría, Carmen Guaza, Javier Fernández-Ruiz & Eva de Lago. (2012) Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. Neuroscience Letters 508:2, pages 67-72.
Crossref
Crossref
Akhlaq A. FarooquiAkhlaq A. Farooqui. 2011. Lipid Mediators and Their Metabolism in the Brain. Lipid Mediators and Their Metabolism in the Brain
133
157
.
M.J. Dowie, M.L. Howard, L.F.B. Nicholson, R.L.M. Faull, A.J. Hannan & M. Glass. (2010) Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience 170:1, pages 324-336.
Crossref
Crossref
Gregory T. CarterMary E. Abood, Sunil K. Aggarwal & Michael D. Weiss. (2010) Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials. American Journal of Hospice and Palliative Medicine® 27:5, pages 347-356.
Crossref
Crossref
Silvia Rossi, Giorgio Bernardi & Diego Centonze. (2010) The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Experimental Neurology 224:1, pages 92-102.
Crossref
Crossref
Emma L Scotter, Mary E Abood & Michelle Glass. (2010) The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology 160:3, pages 480-498.
Crossref
Crossref
DAWN FALLIK. (2010) As Another State Approves Medical Marijuana, Neurologists Urge Caution About Prescribing. Neurology Today 10:4, pages 1.
Crossref
Crossref
Roger G. Pertwee & Adèle Thomas. 2009. The Cannabinoid Receptors. The Cannabinoid Receptors
361
392
.
Hidefumi Ito, Reika Wate, Jianhua Zhang, Shizuo Ohnishi, Satoshi Kaneko, Hisashi Ito, Satoshi Nakano & Hirofumi Kusaka. (2008) Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Experimental Neurology 213:2, pages 448-455.
Crossref
Crossref
B. Jane Distad, Gregg D. Meekins, Lee L. Liou, Michael D. Weiss, Gregory T. Carter & Robert G. Miller. (2008) Drug Therapy in Amyotrophic Lateral Sclerosis. Physical Medicine and Rehabilitation Clinics of North America 19:3, pages 633-651.
Crossref
Crossref
Roger G. Pertwee. (2008) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addiction Biology 13:2, pages 147-159.
Crossref
Crossref
Aoife Gowran & Veronica A. Campbell. (2008)
A role for p53 in the regulation of lysosomal permeability by Δ
9
-tetrahydrocannabinol in rat cortical neurones: implications for neurodegeneration
. Journal of Neurochemistry 105:4, pages 1513-1524.
Crossref
Crossref
Pingwei Zhao, Sheila Ignacio, Eric C. Beattie & Mary E. Abood. (2008) Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. European Journal of Neuroscience 27:3, pages 572-579.
Crossref
Crossref
Gareth Pryce, Sam J. Jackson & David Baker. 2008. Cannabinoids and the Brain. Cannabinoids and the Brain
375
394
.
Sean D. McAllister, Rigel T. Christian, Maxx P. Horowitz, Amaia Garcia & Pierre-Yves Desprez. (2007) Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics 6:11, pages 2921-2927.
Crossref
Crossref
D Baker, S J Jackson & G Pryce. (2007) Cannabinoid control of neuroinflammation related to multiple sclerosis. British Journal of Pharmacology 152:5, pages 649-654.
Crossref
Crossref
Eric J. Downer, Aoife Gowran & Veronica A. Campbell. (2007) A comparison of the apoptotic effect of Δ9-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Research 1175, pages 39-47.
Crossref
Crossref
Barbara Costa. (2007)
On the Pharmacological Properties of Δ
9
‐Tetrahydrocannabinol (THC)
. Chemistry & Biodiversity 4:8, pages 1664-1677.
Crossref
Crossref
Mark. P. Mattson, Tae Gen Son & Simonetta Camandola. (2007) Viewpoint: Mechanisms of Action and Therapeutic Potential of Neurohormetic Phytochemicals. Dose-Response 5:3, pages dose-response.0.
Crossref
Crossref
Jennifer L. Shoemaker, Kathryn A. Seely, Ronald L. Reed, John P. Crow & Paul L. Prather. (2006) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Journal of Neurochemistry 101:1, pages 87-98.
Crossref
Crossref
Diego Centonze, Alessandro Finazzi-Agrò, Giorgio Bernardi & Mauro Maccarrone. (2007) The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends in Pharmacological Sciences 28:4, pages 180-187.
Crossref
Crossref
Michael Benatar. (2007) Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiology of Disease 26:1, pages 1-13.
Crossref
Crossref
Diego Centonze, Silvia Rossi, Alessandro Finazzi‐Agrò, Giorgio Bernardi & Mauro Maccarrone. 2007. Neuroinflammation in Neuronal Death and Repair. Neuroinflammation in Neuronal Death and Repair
171
186
.
Hans Gerhard Vogel. 2008. Drug Discovery and Evaluation. Drug Discovery and Evaluation
565
876
.
Pál Pacher, Sándor Bátkai & George Kunos. (2006) The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews 58:3, pages 389-462.
Crossref
Crossref
Kathline Kim, Dan H. Moore, Alexandros Makriyannis & Mary E. Abood. (2006) AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. European Journal of Pharmacology 542:1-3, pages 100-105.
Crossref
Crossref
Hanneke Bunte, Martijn Schenning, Peter Sodaar, Dop P. R. Bär, Karel W. A. Wirtz, Freek L. van Muiswinkel & Gerry T. Snoek. (2006) A phosphatidylinositol transfer protein α-dependent survival factor protects cultured primary neurons against serum deprivation-induced cell death. Journal of Neurochemistry 97:3, pages 707-715.
Crossref
Crossref
Lynsey G. Bilsland, James R. T. Dick, Gareth Pryce, Stefania Petrosino, Vincenzo Di Marzo, David Baker, Linda Greensmith, Lynsey G. Bilsland, James R. T. Dick, Gareth Pryce, Stefania Petrosino, Vincenzo Di Marzo, David Baker & Linda Greensmith. (2006) Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice. The FASEB Journal 20:7, pages 1003-1005.
Crossref
Crossref
Mark F. McCarty. (2006) Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Medical Hypotheses 67:2, pages 251-269.
Crossref
Crossref
Niranjanan Nirmalananthan & Linda Greensmith. (2005) Amyotrophic lateral sclerosis: recent advances and future therapies. Current Opinion in Neurology 18:6, pages 712-719.
Crossref
Crossref
Isabel Lastres-Becker, Francisco Molina-Holgado, José A. Ramos, Raphael Mechoulam & Javier Fernández-Ruiz. (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiology of Disease 19:1-2, pages 96-107.
Crossref
Crossref
Edith G McGeer & Patrick L McGeer. (2005) Pharmacologic Approaches to the Treatment of Amyotrophic Lateral Sclerosis. BioDrugs 19:1, pages 31-37.
Crossref
Crossref
Javier Fernández-Ruiz, Sara González, Julián Romero & José Antonio Ramos. 2005. Cannabinoids as Therapeutics. Cannabinoids as Therapeutics
79
109
.